Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index. The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index.
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma.Presented data supporting RTNova (CLD-400), the company’s...
- RTNova, an innovative systemic antitumor enveloped virotherapy, unlocks new possibilities in cancer therapy - RTNova addresses challenges posed by untargetable and untreatable metastatic...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0679 | -7.18518518519 | 0.945 | 0.9471 | 0.83 | 940928 | 0.90639147 | CS |
| 4 | -0.4929 | -35.9781021898 | 1.37 | 1.53 | 0.818 | 1234971 | 1.18195695 | CS |
| 12 | -0.2629 | -23.0614035088 | 1.14 | 3.89 | 0.818 | 1905922 | 2.07151765 | CS |
| 26 | -1.0129 | -53.5925925926 | 1.89 | 3.89 | 0.73 | 1006144 | 1.93710925 | CS |
| 52 | -10.3229 | -92.16875 | 11.2 | 16.8 | 0.73 | 1039853 | 2.57505104 | CS |
| 156 | -44.2229 | -98.055210643 | 45.1 | 50 | 0.73 | 784814 | 3.03453305 | CS |
| 260 | -44.2229 | -98.055210643 | 45.1 | 50 | 0.73 | 784814 | 3.03453305 | CS |
| Symbol | Preis | Vol. |
|---|---|---|
| EONREON Resources Inc | US$ 1,33 (30,39%) | 133,45M |
| MSTUT Rex 2X Long MSTR Daily Target ETF | US$ 12,685 (-3,39%) | 66,6M |
| SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 33,69 (3,69%) | 60,46M |
| SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 5,79 (-2,53%) | 52,66M |
| TSLZT Rex 2X Inverse Tesla Daily Target ETF | US$ 2,13 (1,43%) | 48,58M |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
